Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Parkinson's disease
Biotech
Roche's Prothena-partnered Parkinson's prospect fails phase 2b
Days after the failure of UCB's Novartis-partnered program, Roche has shared details of its own alpha-synuclein flop while clinging onto signs of clinical benefit.
Nick Paul Taylor
Dec 19, 2024 4:31am
UCB-Novartis Parkinson's asset fails to improve symptoms in ph. 2
Dec 16, 2024 3:19pm
Cala raises $50M to boost its wearable hand tremor therapy
Dec 9, 2024 10:58am
AbbVie's Parkinson's prospect improves motor function in ph. 3
Dec 9, 2024 9:34am
Misconduct and the future of neurodegenerative disease research
Nov 15, 2024 9:06am
GSK pays Flagship biotech $80M for preclinical neuro pact
Nov 12, 2024 6:30am
